• Thu, December 14, 2017
  • Fri, December 15, 2017
  • Mon, December 18, 2017
  • Tue, December 19, 2017

Liana Moussatos Upgraded (BMRN) to Buy on, Dec 14th, 2017

Liana Moussatos of Wedbush, Upgraded "BioMarin Pharmaceutical Inc." (BMRN) to Buy on, Dec 14th, 2017.

Liana has made no other calls on BMRN in the last 4 months.



There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 1 agrees with Liana's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kennen MacKay of "RBC Capital" Initiated at Hold and Held Target at $93 on, Friday, September 15th, 2017


These are the ratings of the 7 analyists that currently disagree with Liana


  • M. Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $119 on, Friday, October 27th, 2017
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $105 on, Friday, October 27th, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $124 on, Thursday, October 19th, 2017
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $142 on, Thursday, October 19th, 2017
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $117 on, Friday, October 6th, 2017
  • Christopher Raymond of "Piper Sandler" Initiated at Buy on, Thursday, September 14th, 2017
  • Josh Schimmer of "Evercore ISI Group" Initiated at Buy on, Thursday, August 17th, 2017